Form D · Pharmaceuticals
Coeptis Pharmaceuticals, Inc.
Wexford, PA · CIK 0001760174
Offering snapshot reported Jan 28, 2021 · SEC filing
- Reported sold
- $597K Offering amount: $5M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Jan 13, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 28, 2021 | Initial | $597,000 | No comparison | 9 | SEC filing |
| Dec 22, 2020 | Initial | $917,500 | No comparison | 16 | SEC filing |
| Nov 28, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-387690
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| N/A | None |
Source: Form D, filed Jan 28, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Mehalick | Director, Executive, Promoter |
| Christine Sheehy | Director, Executive |
| Dan Yerace | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
105 Bradford Road Suite 420
Wexford, PA, 15090
Wexford, PA, 15090